Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 831 to 840 of 1000 total matches.
Vorinostat (Zolinza) for Cutaneous T-cell Lymphoma
The Medical Letter on Drugs and Therapeutics • Mar 12, 2007 (Issue 1256)
School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New ...
Vorinostat (Zolinza - Merck), an oral histone deacetylase (HDAC) inhibitor, has received accelerated approval from the FDA for treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) that is persistent, progressive or recurrent after two systemic therapies. The most common types of CTCL are mycosis fungoides and SΘzary syndrome, the leukemic form of mycosis fungoides.
Once-Daily Mesalamine (Lialda) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 26, 2007 (Issue 1257)
of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New York ...
A once-daily oral formulation of mesalamine (Lialda - Shire) was recently approved by the FDA for induction of remission in patients with mild to moderate ulcerative colitis.
Panitumumab (Vectibix) for Metastatic Colorectal Cancer
The Medical Letter on Drugs and Therapeutics • Apr 23, 2007 (Issue 1259)
., Vanderbilt University School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H ...
Panitumumab (Vectibix - Amgen), a fully human IgG2 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), has been approved by the FDA for treatment of patients with EGFR-expressing metastatic colorectal cancer that has progressed despite standard chemotherapy. It is the second monoclonal antibody EGFR inhibitor to be approved for metastatic colorectal cancer; cetuximab (Erbitux), a human-murine chimeric IgG1 monoclonal antibody, was approved in 2004.
Palatal Implants for Snoring and Obstructive Sleep Apnea
The Medical Letter on Drugs and Therapeutics • Mar 24, 2008 (Issue 1282)
School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New ...
Treatment options for snoring and obstructive sleep apnea (OSA) now include, in addition to lifestyle remedies such as weight loss and avoidance of alcohol in the evening, mechanical devices, injection of botulinum toxin into the soft palate and a variety of ENT surgical outpatient procedures. Palatal implants (Pillar procedure - Restore Medical Inc) have been approved by the FDA for treatment of snoring and OSA.
Ciclesonide (Omnaris) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • May 05, 2008 (Issue 1285)
School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New ...
Ciclesonide (Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial allergic rhinitis (PAR) in those ≥12 years old. An orally inhaled formulation of ciclesonide (Alvesco) was recently approved by the FDA for maintenance treatment of asthma, and will be reviewed in a future issue of The Medical Letter
Pharmacogenetic-Based Dosing of Warfarin
The Medical Letter on Drugs and Therapeutics • May 19, 2008 (Issue 1286)
School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New ...
Warfarin sodium (Coumadin, and others) and other coumarin anticoagulants prevent thrombosis, but patient response is highly variable and overanticoagulation can lead to hemorrhage. Genotyping patients for single nucleotide polymorphisms (SNPs) that affect coumarin metabolism and sensitivity may help clinicians estimate the therapeutic warfarin dose. The FDA has added a note to warfarin labeling recommending lowrange doses for patients with such genetic variations. Commercial tests for these variants are now available and cost about $500 per test.
Drugs for Travelers' Diarrhea
The Medical Letter on Drugs and Therapeutics • Jul 28, 2008 (Issue 1291)
. Roden, M.D., Vanderbilt University School of Medicine
F. Estelle R. Simons, M.D., University ...
The most common cause of travelers' diarrhea, usually a self-limited illness without fever lasting several days, is infection with noninvasive enterotoxigenic (ETEC) or enteroaggregative (EAEC) strains of Escherichia coli. Campylobacter, Shigella, Salmonella, Aeromonas, viruses and parasites are less common.
Aliskiren/Hydrochlorothiazide (Tekturna HCT) for Hypertension
The Medical Letter on Drugs and Therapeutics • Aug 25, 2008 (Issue 1293)
School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New ...
Aliskiren (Tekturna - Novartis), the first direct renin inhibitor for treatment of hypertension, has been approved for use in a fixed-dose combination with the diuretic hydrochlorothiazide (Tekturna HCT - Novartis). Many angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are also available in fixed-dose combinations with hydrochlorothiazide (HCTZ).
Ciclesonide (Alvesco) - A New Inhaled Corticosteroid for Asthma
The Medical Letter on Drugs and Therapeutics • Sep 22, 2008 (Issue 1295)
., Vanderbilt University School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H ...
The FDA has approved the marketing of the corticosteroid ciclesonide (Alvesco - Sepracor) in a hydrofluoroalkane (HFA) metered-dose inhaler formulation for maintenance treatment of asthma in patients >12 years old. Ciclesonide is also available in the US as a nasal spray for allergic rhinitis (Omnaris), and has been available for asthma in Europe since 2003.
Certolizumab (Cimzia) for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008 (Issue 1297)
., Vanderbilt University School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H ...
The FDA has approved the marketing of certolizumab pegol (Cimzia - UCB), a tumor necrosis factor (TNF) blocker, for treatment of moderate to severe Crohn's disease refractory to conventional treatment. It is the third TNF blocker approved for this indication.